Intellia Therapeutics (NTLA) Leases: 2019-2025
Historic Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Sep 2025 value amounting to $117.9 million.
- Intellia Therapeutics' Leases rose 17.49% to $117.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.9 million, marking a year-over-year increase of 17.49%. This contributed to the annual value of $219.3 million for FY2024, which is 90.07% up from last year.
- Latest data reveals that Intellia Therapeutics reported Leases of $117.9 million as of Q3 2025, which was down 8.65% from $129.0 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Leases ranged from a high of $219.3 million in Q4 2024 and a low of $1.4 million during Q2 2021.
- In the last 3 years, Intellia Therapeutics' Leases had a median value of $118.8 million in 2023 and averaged $127.8 million.
- Its Leases has fluctuated over the past 5 years, first crashed by 94.03% in 2021, then surged by 5,169.64% in 2022.
- Over the past 5 years, Intellia Therapeutics' Leases (Quarterly) stood at $79.1 million in 2021, then spiked by 68.15% to $133.1 million in 2022, then fell by 13.30% to $115.4 million in 2023, then soared by 90.07% to $219.3 million in 2024, then climbed by 17.49% to $117.9 million in 2025.
- Its Leases stands at $117.9 million for Q3 2025, versus $129.0 million for Q2 2025 and $138.0 million for Q1 2025.